What question did this study set out to answer?

The study aims to assess the efficacy and safety of inebilizumab in patients with AQP4 antibody-positive neuromyelitis optica spectrum disorder.

June 13, 2026Neurology

A Real-world Study of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: One-year Follow up Results (P6-1.004)

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates efficacy and safety of inebilizumab in Chinese patients with NMOSD, highlighting its potential benefits.

The study aims to assess the efficacy and safety of inebilizumab in patients with AQP4 antibody-positive neuromyelitis optica spectrum disorder.
Multicenter trial across different locations in China
Evaluated a large sample of patients with NMOSD
Safety and efficacy analysis over one year
Demonstrated significant efficacy of inebilizumab in reducing relapse rates
Safety profile of inebilizumab found acceptable with minimal adverse events
Positive outcomes noted for quality of life improvements in treated patients

Gui et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark